Philipp Trube specialises in German and European antitrust, competition and public procurement law. He advises German and international clients before the European Commission, the Federal Cartel Office and before the procurement review bodies.
Languages: German, English
- Representing Vodafone before the courts in relation to a successful third-party intervention against a Bundeskartellamt decision clearing a joint venture between Deutsche Telekom and EWE subject to remedies
- Advising and representing CRRC as a third party in the merger control proceedings Alstom/Bombardier
- Advising leading Chinese locomotive manufacturer CRRC on the merger control aspects of its acquisition of Vossloh Locomotives (complex phase II proceedings before the Bundeskartellamt)
- Advising the Monitoring Trustee in various European Commission remedy cases (inter alia, case AT.39816 – Gazprom and case M.9234 – Harris Corporation/L3 Technologies)
- Merger control advice to OpenGate, i.a. on the acquisition of a business unit from Danaher Corporation
- Advising UPLINK Network before the Bundeskartellamt and in courts in relation to the dispute around access to radio antennas
- Advising an industry association in an action for annulment before the European Court of Justice
- Advising a telecommunications company on the antitrust admissibility of distribution arrangements
- Representing an active nutrition supplier in merger control proceedings
- Advising a company active in the beverage industry on distribution issues
- Advising a trading company on excise tax issues
Philipp studied at the University of Bayreuth, the Université de Lausanne and the Humboldt University of Berlin with a focus on intellectual property law and German and European antitrust law. He trained at large international law firms including Freshfields Bruckhaus Deringer LLP in the field of antitrust law.
Philipp completed his legal clerkship at the Higher Regional Court of Berlin, inter alia at kwm Rechtsanwälte and Siemens in Berlin. Philipp’s doctoral thesis deals with legal aspects of pharmacological neuroenhancement (ongoing Ph.D. project).